Dr. Lal PathLabs 将来の成長

Future 基準チェック /36

Dr. Lal PathLabs利益と収益がそれぞれ年間11.5%と10.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に22.5% 11.2%なると予測されています。

主要情報

11.5%

収益成長率

11.23%

EPS成長率

Healthcare 収益成長	27.2%
収益成長率	10.7%
将来の株主資本利益率	22.53%
アナリストカバレッジ	Good
最終更新日	26 Sep 2025

今後の成長に関する最新情報

Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Aug 05

Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report

Feb 03

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Oct 26

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04

Recent updates

Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Aug 05

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Shares May Have Run Too Fast Too Soon

Jul 25

Is Now The Time To Put Dr. Lal PathLabs (NSE:LALPATHLAB) On Your Watchlist?

Jun 24

Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Jun 03

Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Apr 28

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Business Is Trailing The Market But Its Shares Aren't

Apr 25

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Mar 04

Expansion Into Tier 2 And Tier 3 Towns Will Enhance Access To Diagnostic Services In India

Feb 18 Government health spending and rising NCD prevalence are likely to boost Dr. Lal PathLabs' patient volumes and revenues.

Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report

Feb 03

Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking

Jan 16

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jan 01

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Oct 26

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Oct 24

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

Oct 06

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Jul 07

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 10

業績と収益の成長予測

NSEI:LALPATHLAB - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2028	34,379	6,977	7,357	N/A	14
3/31/2027	30,866	6,035	6,409	N/A	23
3/31/2026	27,522	5,166	5,567	N/A	23
6/30/2025	25,293	5,131	N/A	N/A	N/A
3/31/2025	24,614	4,871	5,150	5,689	N/A
12/31/2024	24,042	4,168	N/A	N/A	N/A
9/30/2024	23,464	4,014	4,912	5,365	N/A
6/30/2024	22,875	3,815	N/A	N/A	N/A
3/31/2024	22,266	3,577	4,779	5,353	N/A
12/31/2023	21,722	3,298	N/A	N/A	N/A
9/30/2023	21,227	3,013	4,767	5,198	N/A
6/30/2023	20,552	2,638	N/A	N/A	N/A
3/31/2023	20,169	2,388	4,115	4,560	N/A
12/31/2022	20,114	2,435	N/A	N/A	N/A
9/30/2022	20,189	2,480	-824	3,884	N/A
6/30/2022	19,835	2,713	N/A	N/A	N/A
3/31/2022	20,874	3,448	-294	4,467	N/A
12/31/2021	20,329	3,669	N/A	N/A	N/A
9/30/2021	19,884	4,041	4,609	5,327	N/A
6/30/2021	19,219	3,944	N/A	N/A	N/A
3/31/2021	15,813	2,916	3,386	3,982	N/A
12/31/2020	14,520	2,407	N/A	N/A	N/A
9/30/2020	13,275	2,003	2,259	2,821	N/A
6/30/2020	12,612	1,955	N/A	N/A	N/A
3/31/2020	13,304	2,259	2,043	2,839	N/A
12/31/2019	13,298	2,405	N/A	N/A	N/A
9/30/2019	12,944	2,322	2,199	2,619	N/A
6/30/2019	12,463	2,086	N/A	N/A	N/A
3/31/2019	12,034	1,992	N/A	2,185	N/A
12/31/2018	11,691	1,923	N/A	N/A	N/A
9/30/2018	11,393	1,825	N/A	N/A	N/A
6/30/2018	10,999	1,761	N/A	N/A	N/A
3/31/2018	10,569	1,707	N/A	1,971	N/A
12/31/2017	10,100	1,617	N/A	N/A	N/A
9/30/2017	9,548	1,565	N/A	N/A	N/A
6/30/2017	9,389	1,586	N/A	N/A	N/A
3/31/2017	9,124	1,546	N/A	1,713	N/A
12/31/2016	8,902	1,576	N/A	N/A	N/A
9/30/2016	8,713	1,876	N/A	N/A	N/A
6/30/2016	8,249	1,413	N/A	N/A	N/A
3/31/2016	7,913	1,322	N/A	1,585	N/A
12/31/2015	7,654	1,201	N/A	N/A	N/A
3/31/2015	6,596	908	N/A	1,218	N/A

アナリストによる今後の成長予測

収入対貯蓄率: LALPATHLABの予測収益成長率 (年間11.5% ) は貯蓄率 ( 6.8% ) を上回っています。

収益対市場: LALPATHLABの収益 ( 11.5% ) Indian市場 ( 15.9% ) よりも低い成長が予測されています。

高成長収益: LALPATHLABの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: LALPATHLABの収益 ( 10.7% ) Indian市場 ( 10.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: LALPATHLABの収益 ( 10.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LALPATHLABの自己資本利益率は、3年後には高くなると予測されています ( 22.5 %)

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/10/06 11:29
終値	2025/10/06 00:00
収益	2025/06/30
年間収益	2025/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Dr. Lal PathLabs Limited 23 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。52

アナリスト	機関
Ashwin Mehta	Ambit Capital
Nitin Bhasin	Ambit Capital
Prashant Nair	Ambit Capital

Dr. Lal PathLabs 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Price target increased by 12% to ₹2,924

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Price target increased by 8.0% to ₹2,353

Recent updates

Here's Why We Think Dr. Lal PathLabs (NSE:LALPATHLAB) Is Well Worth Watching

Under The Bonnet, Dr. Lal PathLabs' (NSE:LALPATHLAB) Returns Look Impressive

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

First quarter 2026 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Shares May Have Run Too Fast Too Soon

Dr. Lal PathLabs Limited to Report Q1, 2026 Results on Jul 31, 2025

Is Now The Time To Put Dr. Lal PathLabs (NSE:LALPATHLAB) On Your Watchlist?

Full year 2025 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Upcoming dividend of ₹6.00 per share

Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Fourth quarter dividend of ₹6.00 announced

Full year 2025 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 28, 2025

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Business Is Trailing The Market But Its Shares Aren't

Dr. Lal PathLabs Limited to Report Q4, 2025 Results on Apr 25, 2025

Dr. Lal Pathlabs Limited Launches Advanced Test for Amyloidosis

MD & Director recently sold ₹51m worth of stock

MD & Director recently sold ₹43m worth of stock

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Expansion Into Tier 2 And Tier 3 Towns Will Enhance Access To Diagnostic Services In India

MD & Director recently sold ₹28m worth of stock

Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report

Third quarter 2025 earnings: EPS misses analyst expectations

Dr. Lal Pathlabs Limited Approves Declaration Third Interim Dividend for Financial Year 2024-25

Dr. Lal PathLabs Limited to Report Q3, 2025 Results on Jan 30, 2025

Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking

Non Executive Director recently sold ₹15m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

MD & Director recently sold ₹79m worth of stock

MD & Director recently sold ₹35m worth of stock

Company Secretary & Compliance Officer recently sold ₹1.7m worth of stock

Upcoming dividend of ₹6.00 per share

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025

Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

MD & Director recently sold ₹28m worth of stock

Price target increased by 12% to ₹2,924

First quarter 2025 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs Limited Approves Interim Dividend for the Fiscal Year 2024-25

Dr. Lal PathLabs Limited to Report Q1, 2025 Results on Aug 07, 2024

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Non Executive Director recently sold ₹14m worth of stock

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

Upcoming dividend of ₹6.00 per share

MD & Director recently sold ₹29m worth of stock

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

MD & Director recently sold ₹36m worth of stock

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024